A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

NCT00500006 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Interventions

DRUG: MK0457
DRUG: dasatinib

Sponsor

Merck Sharp & Dohme LLC